Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.
Researchers found high rates of dyslipidemia and abnormal HbA1c, including 2 cases of diabetes, after screening for cardiovascular risk factors in middle school students.
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
Treatment with icosapent ethyl was associated with a substantial reduction in the risk of first, subsequent, and total ischemic events when compared with placebo in statin-treated patients with established cardiovascular (CV) disease or diabetes with other CV risk factors.
Clinics in the United States varied widely in their adherence to statin recommendations, which was associated with wide differences in low-density lipoprotein cholesterol control.
